John Militello - 26 May 2026 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Reporting relationship: Vice President of Finance, Treasurer, Principal Accounting Officer
Issuer ticker: RCKT
Reported as of: 26 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 May 2026, 16:33:19 UTC
Prior SEC filing: 21 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Martin Wilson, as attorney-in-fact for John Militello

Key filing fact

John Militello filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 28 May 2026.

Key facts

This page summarizes John Militello's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
17 reported transactions and 17 derivative rows are listed below.
Accepted by SEC: 28 May 2026, 16:33.

Change

Previous filing in this sequence was filed on 21 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001662170 Primary reporting owner

Militello John

Relationship: Vice President of Finance, Treasurer, Principal Accounting Officer
Address: C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY
Signature: /s/ Martin Wilson, as attorney-in-fact for John Militello
Signature date: 28 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCKT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -10,000
Change %: -100%
Price
Shares after: 0
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $18.75
Footnotes: F1, F2

RCKT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -10,000
Change %: -100%
Price
Shares after: 0
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $20.61
Footnotes: F1, F3

RCKT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -20,000
Change %: -100%
Price
Shares after: 0
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $14.56
Footnotes: F1, F4

RCKT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -10,000
Change %: -100%
Price
Shares after: 0
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $10.85
Footnotes: F1, F5

RCKT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -20,000
Change %: -100%
Price
Shares after: 0
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $22.72
Footnotes: F1, F6

RCKT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -2,000
Change %: -100%
Price
Shares after: 0
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,000
Exercise price: $23.89
Footnotes: F1, F7

RCKT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -18,000
Change %: -100%
Price
Shares after: 0
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,000
Exercise price: $24.82
Footnotes: F1, F8

RCKT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -18,000
Change %: -100%
Price
Shares after: 0
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,000
Exercise price: $62.32
Footnotes: F1, F9

RCKT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -27,003
Change %: -100%
Price
Shares after: 0
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,003
Exercise price: $19.05
Footnotes: F1, F10

RCKT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -28,910
Change %: -100%
Price
Shares after: 0
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,910
Exercise price: $13.12
Footnotes: F1, F11

RCKT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -49,798
Change %: -100%
Price
Shares after: 0
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 49,798
Exercise price: $20.04
Footnotes: F1, F12

RCKT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -24,545
Change %: -100%
Price
Shares after: 0
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,545
Exercise price: $30.01
Footnotes: F1, F13

RCKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +51,509
Change %
Price
Shares after: 51,509
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 51,509
Exercise price: $3.00
Footnotes: F1, F14

RCKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +15,002
Change %
Price
Shares after: 15,002
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,002
Exercise price: $3.00
Footnotes: F1, F14

RCKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +16,061
Change %
Price
Shares after: 16,061
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,061
Exercise price: $3.00
Footnotes: F1, F14

RCKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +24,899
Change %
Price
Shares after: 24,899
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,899
Exercise price: $3.00
Footnotes: F1, F14

RCKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +9,091
Change %
Price
Shares after: 9,091
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,091
Exercise price: $3.00
Footnotes: F1, F15

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 15 footnotes

Footnote F1

On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026.

Footnote F2

This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on March 29, 2019, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Footnote F3

This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on June 25, 2019, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Footnote F4

This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, 6,672 of which will become fully vested and exercisable on January 28, 2020, with the remaining 13,328 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Footnote F5

This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on September 2, 2020, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Footnote F6

This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 6, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Footnote F7

This option represents a right to purchase a total of 2,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 10, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Footnote F8

This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on August 3, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Footnote F9

The option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 4, 2022, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Footnote F10

This option represents a right to purchase a total of 27,003 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Footnote F11

This option represents a right to purchase a total of 28,910 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Footnote F12

This option represents a right to purchase a total of 49,798 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Footnote F13

This option represents a right to purchase a total of 24,545 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 16, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Footnote F14

Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer.

Footnote F15

This option represents a right to purchase a total of 9,091 shares of the Issuer's common stock, one-half of which will become fully vested and exercisable on May 26, 2027, with the remaining shares becoming fully vested and exercisable on May 26, 2028, in each case, subject to the reporting person's continued employment with the Issuer.

SEC remarks

Vice President of Finance, Treasurer, Principal Accounting Officer